Article Abstract

The role of glutamate transport and SLC7A11 expression in tumor-associate seizures and survival in patients with malignant gliomas

Authors: Joseph R. Keen, Sharon A. Swanger, Stephen F. Traynelis, Jeffrey J. Olson


Treatment for glioblastoma (GBM) remains largely palliative despite maximal combined approaches (surgery, radiation, and chemotherapy) with a median survival of approximately 15 months due to relentless invasion and recurrence (1). Even with advances in drug delivery, molecular targeting, and immunomodulative therapy, prognosis is grave (2) and the clinical course is characterized by progressive, symptomatic decline secondary to edema, invasion of eloquent areas, and seizures.


  • There are currently no refbacks.

Article Options

Download Citation